229 related articles for article (PubMed ID: 31802055)
1. Use of amyloid PET/CT with
Ferrari C; Caputo P; Pisani AR; Nappi AG; Branca A; Lavelli V; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():142-152. PubMed ID: 31802055
[TBL] [Abstract][Full Text] [Related]
2. 18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification.
Alongi P; Sardina DS; Coppola R; Scalisi S; Puglisi V; Arnone A; Raimondo GD; Munerati E; Alaimo V; Midiri F; Russo G; Stefano A; Giugno R; Piccoli T; Midiri M; Grimaldi LME
J Neuroimaging; 2019 May; 29(3):383-393. PubMed ID: 30714241
[TBL] [Abstract][Full Text] [Related]
3. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
4. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
5. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
6. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
8. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
9. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
10. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
11. Coupled Imaging with [
Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
[TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of [
Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
[TBL] [Abstract][Full Text] [Related]
13. [
Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of early-phase [
Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
[TBL] [Abstract][Full Text] [Related]
15. [Amyloid positron-emission-tomography with [
Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
[TBL] [Abstract][Full Text] [Related]
16. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
[TBL] [Abstract][Full Text] [Related]
17. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers.
Tiepolt S; Barthel H; Butzke D; Hesse S; Patt M; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):238-44. PubMed ID: 23104671
[TBL] [Abstract][Full Text] [Related]
18. The role of PET/CT amyloid Imaging compared with Tc99m-HMPAO SPECT imaging for diagnosing Alzheimer's disease.
Suppiah S; Ching SM; Nordin AJ; Vinjamuri S
Med J Malaysia; 2018 Jun; 73(3):141-146. PubMed ID: 29962497
[TBL] [Abstract][Full Text] [Related]
19. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
20. Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer's Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins.
Manca C; Hopes L; Kearney-Schwartz A; Roch V; Karcher G; Baumann C; Marie PY; Malaplate-Armand C; Jonveaux TR; Verger A
J Alzheimers Dis; 2019; 68(3):1061-1069. PubMed ID: 30883358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
